StreetAlpha.app
Home › Stocks › KRSA

Korsana Biosciences, Inc. (KRSA)

Healthcare
$37.56
▲ +5.95%
LAST CLOSE · NOV 20

Korsana Biosciences is developing CYC-126, a personalized anesthesia treatment for depression that has not responded to standard antidepressants. It last closed at $37.56 on Nov 20, up 5.95% on the day. For the quarter ended Sep 2026, KRSA reported EPS of -$3.19.

AI Auto Pilots
Is KRSA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KRSA.

Key Stats

Last 12 months
Results
Net income
−$58.9M
Valuation
Market cap
$1.7B
45.5M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$456.2M
At Sep 30
Shareholder equity
$391.6M
Shares outstanding
45.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.9M$3.9MFY2021FY2022: $297K$297KFY2022FY2023: $0$0FY2023FY2024: $2.0M$2.0MFY2024FY2025: $2.1M$2.1MFY2025

From KRSA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$3.19
Quarter ended Sep 2026
Year ago EPS
-$39.49
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.22Dec '24Mar 2025: -$0.56Mar '25Jun 2025: -$0.11Jun '25Sep 2025: -$39.49Sep '25Dec 2025: $46.56Dec '25Mar 2026: -$0.76Mar '26Jun 2026: -$0.41Jun '26Sep 2026: -$3.19Sep '26Latest -$3.19
Revenue by quarter
Dec 2024: $1.8MDec '24Mar 2025: $81,000Mar '25Jun 2025: $93,000Jun '25Sep 2025: $875,000Sep '25Dec 2025: $1.0MDec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Latest $0
StreetAlpha's call on KRSAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KRSA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KRSA

Technical Analysis

Sample · made up numbers
SampleMade up numbers, showing what this section looks like for KRSA. AI Starter and AI Pro members see the real figures.Sign up freeSign in
Pullback inside a longer uptrend, nearing oversold

The stock is 8% below its 20 day and 6% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $98.20, and the nearest resistance the Pivot at $102.10.

Short trendBearish
Long trendBullish
MomentumFading
StretchNear oversold
VolatilityNormal, 3.1%/day
Key levels
$121.5052 week high+21.5%
$108.7020 day average+8.7%
$106.4050 day average+6.4%
$103.90Pivot R1+3.9%
$102.10Pivot+2.1%
$100.00Last close
$98.20Pivot S1−1.8%
$96.40Swing low−3.6%
$89.30200 day average−10.7%
$71.2052 week low−28.8%
Indicators
RSI (14)37.20Weak, oversold below 30Neutral
MACD-1.84Below its signal lineBearish
Stochastic24.5Middle of its rangeNeutral
ADX (14)21.4Weak trend
Williams %R-82.5Oversold below −80, overbought above −20Oversold
CCI (20)-121.3Oversold below −100, overbought above 100Oversold
Rate of change−6.2%Change over 10 sessionsBearish
ATR (14)$3.10Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for KRSA

What happened before

See how KRSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KRSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KRSAHow many large options trades hit KRSA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

KRSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲43 buying vs 0 selling
  • ▲Held by funds +86.7 pts
  • ●Funds holding +44
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q3 2026This quarterLast quarterChange
Funds holding44––
In funds' top 109––
Held by funds86.7%––
New / increased43 / 0––
Reduced / sold out0 / 0––
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KRSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRSA is in one of them and how their past KRSA trades turned out.

KRSA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KRSA in an article yet. Here's the latest on the wider market.

About Korsana Biosciences

Korsana Biosciences is a drug developer based in Waltham, Massachusetts, focused on serious neuropsychiatric disorders. Its lead program, CYC-126, is being developed as a treatment for depression that has not responded to at least two antidepressant treatments. The approach combines two widely used anesthetic agents, propofol and dexmedetomidine, with a delivery system that monitors brain activity so dosing can be tailored to each patient. It is designed for use in hospital settings under the care of anesthesiologists. The company is also working to license its older sGC stimulator assets to other firms.

Headquarters
Waltham, MA